The Henri and Belinda Termeer Center for Targeted Therapies is a pioneer in developing genetically-targeted cancer therapies. The Center is comprised of highly talented investigators and clinicians, active in Mass General Hospital’s 29 treatment programs as well as caring for patients. The Termeer Center’s primary goal is to uncover the underlying causes of cancer and identify new targets for precision oncology.
Give them a fighting chance.
In the US, 22% of patients diagnosed with cancer hear the word ‘rare’ and are faced with a probable death sentence. That’s almost 1 in 4.
But we are changing that.
With your support, we can make a real difference.
Rare tumors account for 22% of all cancers and are more difficult to prevent, diagnose and treat than others. Drug development is notoriously slow and finding enough patients able to take part in clinical trials is an ongoing challenge. Rare and Resistant cancers garner little attention from scientific communities, pharmaceutical companies and funding agencies but with your help, we can take action ourselves.
Our primary goal centers around 2 main projects: